Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 10:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Aldosterone Disorder Clear all
Completed Phase 3 Interventional

A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

NCT06168409
View directory record Official record
Conditions
Resistant Hypertension
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Surprise, Arizona • Hollywood, Florida • Lake Worth, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Not applicable Interventional Results available

Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy

NCT01521546
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
eplerenone, placebo
Drug
Lead sponsor
Subha Raman
Other
Eligibility
7 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Phase 4 Interventional

Aldosterone Antagonism in Diastolic Heart Failure

NCT00108251
View directory record Official record
Conditions
Congestive Heart Failure, Diastole
Interventions
Eplerenone, Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

NCT06034743
View directory record Official record
Conditions
Uncontrolled Hypertension, Resistant Hypertension
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
43
States / cities
Saraland, Alabama • Scottsdale, Arizona • Sun City West, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Novel Experimental COVID-19 Therapies Affecting Host Response

NCT04924660
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
Interventions
TXA127, TRV027, Placebo, Fostamatinib
Drug
Lead sponsor
Sean Collins
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
51
States / cities
Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)

NCT01764711
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Cosyntropin administration
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jun 25, 2026, 10:33 PM EDT
Active, not recruiting Phase 4 Interventional

The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans

NCT03938389
View directory record Official record
Conditions
PreDiabetes, Impaired Glucose Tolerance, Obesity, Blood Pressure
Interventions
Sacubitril-Valsartan Tab 97-103 MG, Valsartan 160mg, Placebo Oral Tablet
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Not applicable Interventional Results available

Effect of Azilsartan on Aldosterone in Postmenopausal Females

NCT01774591
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoximil, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Not applicable Interventional Results available

Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)

NCT02740179
View directory record Official record
Conditions
HIV
Interventions
Eplerenone, Placebo, Lifestyle Modification
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension

NCT01996449
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone, Amlodipine, Microneurography, Rhythmic handgrip exercise, Sustained hand grip, Forearm blood flow, Arm cycling exercise, Cold Pressor test
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Jun 25, 2026, 10:33 PM EDT
Completed No phase listed Observational

Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)

NCT05757076
View directory record Official record
Conditions
Primary Aldosteronism
Interventions
Blood test for ARR
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study

NCT01691781
View directory record Official record
Conditions
Hyperparathyroidism
Interventions
Lisinopril
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Phase 4 Interventional Results available

EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia

NCT00187889
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Eplerenone, Placebo or sugar pill
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2013 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Not applicable Interventional Results available

Eplerenone in HIV Associated Abdominal Fat Accumulation

NCT01405456
View directory record Official record
Conditions
HIV
Interventions
Eplerenone and lifestyle, placebo and lifestyle
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Jun 25, 2026, 10:33 PM EDT
Not yet recruiting Phase 2 Interventional

Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans

NCT07602166
View directory record Official record
Conditions
Salt Sensitivity of Blood Pressure, High Blood Pressure, Inflammation, Renin-Angiotensin-Aldosterone System
Interventions
2-hydroxybenzylamine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 25, 2026, 10:33 PM EDT
Completed No phase listed Observational Results available

RAAS and Arterial Stiffness in SCI

NCT04510974
View directory record Official record
Conditions
Arterial Stiffness, Renin Angiotensin Aldosterone System, Orthostatic Hypotension, Spinal Cord Injury, Hypotension
Interventions
Spinal Cord Injury
Other
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
21 Years to 70 Years
Enrollment
33 participants
Timeline
2018 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Jun 25, 2026, 10:33 PM EDT
Completed No phase listed Observational

Adrenal Vein Sampling International Study (AVIS Study)

NCT01234220
View directory record Official record
Conditions
Hyperaldosteronism
Interventions
Not listed
Lead sponsor
University Hospital Padova
Other
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Dallas, Texas • Menomonee Falls, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Jun 25, 2026, 10:33 PM EDT
Terminated Phase 4 Interventional Results available

The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study

NCT02253394
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan plus Spironolactone, Ambrisentan plus Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Jun 25, 2026, 10:33 PM EDT
Withdrawn Not applicable Interventional

Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study

NCT01009944
View directory record Official record
Conditions
Hypertension
Interventions
Lisinopril, Atenolol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

NCT00853827
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Coronary Atherosclerosis
Interventions
Placebo, Aliskiren
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
54
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Not applicable Interventional Results available

Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment

NCT01897727
View directory record Official record
Conditions
Obstructive Sleep Apnea, Resistant Hypertension, Hyperaldosteronism
Interventions
Spironolactone, BP medication uptitration
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Results available

Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function

NCT00094302
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Heart Failure, Congestive
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Carelon Research
Other
Eligibility
50 Years and older
Enrollment
3,445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2015 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

NCT06150924
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
44
States / cities
Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 25, 2026, 10:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress

NCT02431936
View directory record Official record
Conditions
Hypertension, Stress, Psychological, Blood Pressure
Interventions
Prazosin, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Jun 25, 2026, 10:33 PM EDT